Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.

Välittäjätilasto

Dataa ei löytynyt

Yhtiötapahtumat

Datan lähde: FactSet, Quartr

Seuraava tapahtuma
2026 Q4 -tulosraportti 29.5.

Menneet tapahtumat
2026 Q3 -tulosraportti 6.2.
2026 Q2 -tulosraportti 7.11.2025
Ylimääräinen yhtiökokous 2025 10.10.2025
Vuosittainen yhtiökokous 2025 26.9.2025
2026 Q1 -tulosraportti 8.8.2025

Asiakkaat katsoivat myös

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.

Kirjaudu

blueoceanguy
18.2. · Muokattu
·
blueoceanguy
18.2. · Muokattu
·
This post is about Cantourage Group SE, which is the leading German player in the medical cannabis market in Germany/Europe – and the coverage I continuously provide of the company. The background is the recently announced transaction where Organigram Global Inc. acquires Sanity Group GmbH. The headline speaks for itself: ”Organigram to acquire Sanity Group for up-front consideration of €113.4 million plus a maximum earnout of up to €113.8 million tied to financial performance.” The press release can be read here: https://www.organigram.ca/_files/ugd/dad9ab_8cd368c0bdf540ef98a6f62780e15a38.pdf?utm_medium=social&utm_campaign=sanity The transaction involves an upfront payment of €113,4 million and a possible earnout of an additional €113,8 million, bringing the total potential payment to around €227 million. The official valuation table shows that the total potential valuation – including Organigram's existing ownership stake – can reach €250 million. Looking at Sanity's development, growth is as follows: from €9 million in revenue in 2023 to €60 million in 2025, including €19 million in the fourth quarter of 2025 alone. The gross margin has simultaneously improved from 15 % in 2023 to 47 % in 2025. The upfront valuation of €130 million corresponds, according to the announcement, to an LQA-multiple of 1,7x based on Q4 2025 annualized revenue, and the earnout model uses multiples of 1,75x revenue and 12,5x EBITDA. The interesting aspect – and the reason I bring it into the coverage of Cantourage – is the direct comparability. Cantourage delivered revenue of €74,9 million and an EBITDA of €3,9 million in the first nine months of 2025. The market capitalization is around €50 million. In other words: Cantourage generated more revenue in nine months than Sanity did in all of 2025, and yet Cantourage is traded at a market capitalization that is less than half of Sanity's upfront purchase price. Looking at the full earnout structure, the potential payment for Sanity corresponds to more than four times Cantourage's current market cap. This is not a question of comparing two identical companies point by point. It is a reference transaction in the same regulatory environment, the same geographical market, and the same overall value chain. Sanity is described as one of the leading players in Germany and is estimated to have a #2 market position as of January 2026, only surpassed by Cantourage Group. When an international strategic player is willing to pay up to €250 million for a German platform with €60 million in annual revenue and positive EBITDA, it serves as a concrete benchmark for the sector. The German medical cannabis market was estimated in the announcement to be over €2 billion in 2025 with an expectation of more than €4,5 billion in 2028. Consolidation is thus not theoretical – it is underway, and it is happening at multiples significantly above the listed peer valuations. For me, the transaction does not change the fundamentals of Cantourage. But it highlights the asymmetry that currently exists between private M&A pricing and the stock market's valuation. And precisely for this reason, it is relevant in the continued analysis of Cantourage. I maintain my assessment that there is still significant upside in the case around Cantourage Group SE. Looking in isolation at the recently announced transaction regarding Sanity Group GmbH as a reference point, the current valuation of Cantourage appears significantly low. If the market were to apply a similar transaction logic and relative multiples, it indicates, in my assessment, a share price in the range of €6,5–8,0 – potentially higher, if a strategic premium is included. This is, mind you, without adding further upside related to future performance, market shares, etc. The central point is not the precise price target, but the structural point: A concrete, comparable M&A reference has emerged in the same market, and it points to a significant gap between private transaction value and the stock market's current pricing of Cantourage. Disclaimer: I myself have a solid position in Cantourage Group (with entry at a price of €3,02).
anchri3
27.2.
·
anchri3
27.2.
·
Is there a reason the stock keeps falling after the above news?
blueoceanguy
27.2.
·
blueoceanguy
27.2.
·
Falling? We are up more than 20% YTD.
Tunppi82
18.12.2025
·
Tunppi82
18.12.2025
·
-78 🫣
MrPoopenstein
20.2.
MrPoopenstein
20.2.
Still better than me😵‍💫😆
Zinedin Gintonic
12.12.2025
Zinedin Gintonic
12.12.2025
Yeah, just over -98% anymore. 🥳😂
MrPoopenstein
20.2.
MrPoopenstein
20.2.
No idea how the company is doing anymore
salkkumies5
12.12.2025
salkkumies5
12.12.2025
Burn the shorts!!
blueoceanguy
12.12.2025
·
blueoceanguy
12.12.2025
·
Has anyone here looked closer at Cantourage Group SE O.N.? In my assessment, the company appears significantly undervalued. Cantourage is possibly the largest player in the German medical cannabis market, and one of the few that both operates in Germany and is simultaneously listed on the stock exchange. Nevertheless, the stock is traded at a market cap of approx. 300 million DKK (at a price of ~3.00 EUR). The company delivers strong revenue, runs a profitable business, and does it all through an extremely LEAN model: • no own production, and no ambitions to establish production, • focus on regulatory processes, sourcing and distribution, • in addition, also focus on this type of treatment via telemedicine. It is worth noting that Cantourage has not raised capital since their IPO in November 2022, but has nevertheless managed to maintain a solid financial position. If one were to point out a challenge, it has historically been their investor relations and communication to the market. This, however, seems to be changing. They recently hired Manuel Taverne in a brand new role as Head of Investor Relations — a function the company has not previously had. Cantourage itself writes: “With more than 20 years of experience in capital markets and strategic financial communications, Mr. Taverne brings deep expertise in building and maintaining strong investor relations. His appointment underlines Cantourage’s commitment to proactively advancing its capital markets strategy and fostering closer ties with institutional and private investors alike.” They have furthermore recently hired a new CFO, Monique Jaqqam. If they succeed in professionalizing their IR efforts, it could become very interesting for the stock. This is from their Q3-2025: - Revenue up 148% to EUR 75 million in the first nine months of 2025 (ca. 560 mDKK) - On track to become a European player – market liberalization in other European countries offers opportunities - Outlook – Focus on further growth and geographic diversification Berlin, 30 October 2025 – Cantourage Group SE continued its positive business development in the third quarter of 2025 and consolidated its position as one of the leading players in the European medical cannabis market, despite a challenging regulatory environment in Germany. In the third quarter of 2025, Cantourage generated revenue of around EUR 20.1 million (comparable period 2024: EUR 13.2 million). This resulted in total group revenue of around EUR 74.9 million at the end of the third quarter (comparable period 2024: EUR 30.2 million). EBITDA of roughly EUR 3.9 million (comparable period in 2024: EUR 2.1 million) at the end of Q3 2025 underscores the strong operating performance and high scalability of the business model. Disclaimer: I have personally taken a position in the company. Source: https://www.finanzwire.com/press-release/cantourage-group-se-etr-q3-2025-cantourage-delivers-strong-operating-performance-in-a-challenging-regulatory-market-environment-4KFiUufnE4I Company presentation (Feb 2025): https://cdn.prod.website-files.com/6640f5c21aec76e6d2026142/67c9c5b90b00ad609be3b177_202502%20-%20Unternehmenspräsentation%20-%20Cantourage_EN.pdf

Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.

Uutiset

Kaikki uutiset

Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.

Tuotteita joiden kohde-etuutena tämä arvopaperi

2026 Q3 -tulosraportti

47 päivää sitten

Uutiset

Kaikki uutiset

Shareville

Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.

Kirjaudu

blueoceanguy
18.2. · Muokattu
·
blueoceanguy
18.2. · Muokattu
·
This post is about Cantourage Group SE, which is the leading German player in the medical cannabis market in Germany/Europe – and the coverage I continuously provide of the company. The background is the recently announced transaction where Organigram Global Inc. acquires Sanity Group GmbH. The headline speaks for itself: ”Organigram to acquire Sanity Group for up-front consideration of €113.4 million plus a maximum earnout of up to €113.8 million tied to financial performance.” The press release can be read here: https://www.organigram.ca/_files/ugd/dad9ab_8cd368c0bdf540ef98a6f62780e15a38.pdf?utm_medium=social&utm_campaign=sanity The transaction involves an upfront payment of €113,4 million and a possible earnout of an additional €113,8 million, bringing the total potential payment to around €227 million. The official valuation table shows that the total potential valuation – including Organigram's existing ownership stake – can reach €250 million. Looking at Sanity's development, growth is as follows: from €9 million in revenue in 2023 to €60 million in 2025, including €19 million in the fourth quarter of 2025 alone. The gross margin has simultaneously improved from 15 % in 2023 to 47 % in 2025. The upfront valuation of €130 million corresponds, according to the announcement, to an LQA-multiple of 1,7x based on Q4 2025 annualized revenue, and the earnout model uses multiples of 1,75x revenue and 12,5x EBITDA. The interesting aspect – and the reason I bring it into the coverage of Cantourage – is the direct comparability. Cantourage delivered revenue of €74,9 million and an EBITDA of €3,9 million in the first nine months of 2025. The market capitalization is around €50 million. In other words: Cantourage generated more revenue in nine months than Sanity did in all of 2025, and yet Cantourage is traded at a market capitalization that is less than half of Sanity's upfront purchase price. Looking at the full earnout structure, the potential payment for Sanity corresponds to more than four times Cantourage's current market cap. This is not a question of comparing two identical companies point by point. It is a reference transaction in the same regulatory environment, the same geographical market, and the same overall value chain. Sanity is described as one of the leading players in Germany and is estimated to have a #2 market position as of January 2026, only surpassed by Cantourage Group. When an international strategic player is willing to pay up to €250 million for a German platform with €60 million in annual revenue and positive EBITDA, it serves as a concrete benchmark for the sector. The German medical cannabis market was estimated in the announcement to be over €2 billion in 2025 with an expectation of more than €4,5 billion in 2028. Consolidation is thus not theoretical – it is underway, and it is happening at multiples significantly above the listed peer valuations. For me, the transaction does not change the fundamentals of Cantourage. But it highlights the asymmetry that currently exists between private M&A pricing and the stock market's valuation. And precisely for this reason, it is relevant in the continued analysis of Cantourage. I maintain my assessment that there is still significant upside in the case around Cantourage Group SE. Looking in isolation at the recently announced transaction regarding Sanity Group GmbH as a reference point, the current valuation of Cantourage appears significantly low. If the market were to apply a similar transaction logic and relative multiples, it indicates, in my assessment, a share price in the range of €6,5–8,0 – potentially higher, if a strategic premium is included. This is, mind you, without adding further upside related to future performance, market shares, etc. The central point is not the precise price target, but the structural point: A concrete, comparable M&A reference has emerged in the same market, and it points to a significant gap between private transaction value and the stock market's current pricing of Cantourage. Disclaimer: I myself have a solid position in Cantourage Group (with entry at a price of €3,02).
anchri3
27.2.
·
anchri3
27.2.
·
Is there a reason the stock keeps falling after the above news?
blueoceanguy
27.2.
·
blueoceanguy
27.2.
·
Falling? We are up more than 20% YTD.
Tunppi82
18.12.2025
·
Tunppi82
18.12.2025
·
-78 🫣
MrPoopenstein
20.2.
MrPoopenstein
20.2.
Still better than me😵‍💫😆
Zinedin Gintonic
12.12.2025
Zinedin Gintonic
12.12.2025
Yeah, just over -98% anymore. 🥳😂
MrPoopenstein
20.2.
MrPoopenstein
20.2.
No idea how the company is doing anymore
salkkumies5
12.12.2025
salkkumies5
12.12.2025
Burn the shorts!!
blueoceanguy
12.12.2025
·
blueoceanguy
12.12.2025
·
Has anyone here looked closer at Cantourage Group SE O.N.? In my assessment, the company appears significantly undervalued. Cantourage is possibly the largest player in the German medical cannabis market, and one of the few that both operates in Germany and is simultaneously listed on the stock exchange. Nevertheless, the stock is traded at a market cap of approx. 300 million DKK (at a price of ~3.00 EUR). The company delivers strong revenue, runs a profitable business, and does it all through an extremely LEAN model: • no own production, and no ambitions to establish production, • focus on regulatory processes, sourcing and distribution, • in addition, also focus on this type of treatment via telemedicine. It is worth noting that Cantourage has not raised capital since their IPO in November 2022, but has nevertheless managed to maintain a solid financial position. If one were to point out a challenge, it has historically been their investor relations and communication to the market. This, however, seems to be changing. They recently hired Manuel Taverne in a brand new role as Head of Investor Relations — a function the company has not previously had. Cantourage itself writes: “With more than 20 years of experience in capital markets and strategic financial communications, Mr. Taverne brings deep expertise in building and maintaining strong investor relations. His appointment underlines Cantourage’s commitment to proactively advancing its capital markets strategy and fostering closer ties with institutional and private investors alike.” They have furthermore recently hired a new CFO, Monique Jaqqam. If they succeed in professionalizing their IR efforts, it could become very interesting for the stock. This is from their Q3-2025: - Revenue up 148% to EUR 75 million in the first nine months of 2025 (ca. 560 mDKK) - On track to become a European player – market liberalization in other European countries offers opportunities - Outlook – Focus on further growth and geographic diversification Berlin, 30 October 2025 – Cantourage Group SE continued its positive business development in the third quarter of 2025 and consolidated its position as one of the leading players in the European medical cannabis market, despite a challenging regulatory environment in Germany. In the third quarter of 2025, Cantourage generated revenue of around EUR 20.1 million (comparable period 2024: EUR 13.2 million). This resulted in total group revenue of around EUR 74.9 million at the end of the third quarter (comparable period 2024: EUR 30.2 million). EBITDA of roughly EUR 3.9 million (comparable period in 2024: EUR 2.1 million) at the end of Q3 2025 underscores the strong operating performance and high scalability of the business model. Disclaimer: I have personally taken a position in the company. Source: https://www.finanzwire.com/press-release/cantourage-group-se-etr-q3-2025-cantourage-delivers-strong-operating-performance-in-a-challenging-regulatory-market-environment-4KFiUufnE4I Company presentation (Feb 2025): https://cdn.prod.website-files.com/6640f5c21aec76e6d2026142/67c9c5b90b00ad609be3b177_202502%20-%20Unternehmenspräsentation%20-%20Cantourage_EN.pdf